Market news

Nuvation Bio (NYSE:NUVB) presented new subgroup analyses of IBTROZI (taletrectinib) at the 2026 World Conference on Lung Cancer. The data indicated durable and consistent efficacy in advanced ROS1+ non small cell lung cancer regardless of prior chemotherapy exposure. IBTROZI efficacy was reported as consistent across different ROS1 fusion partners in patients with advanced ROS1+ non small cell lung cancer. These IBTROZI subgroup findings matter, but investors may wish to weigh them alongside...

"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Nuvation Bio (NUVB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Nuvation Bio (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The investment bank initiated coverage with an overweight rating.

The mean of analysts' price targets for Nuvation Bio (NUVB) points to a 105.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Nuvation Bio (NUVB) has an average rating of buy and mean price target of $13.10, according to analy

Motley Fool Press Release.

Detailed price information for Nuvation Bio Inc (NUVB-N) from The Globe and Mail including charting and trades.

Nuvation Bio (NUVB) has an average rating of buy and mean price target of $13.22, according to analy

Nuvation Bio Inc. announced that new long-term analyses from its pivotal Phase 2 TRUST-I and TRUST-II trials of IBTROZI (taletrectinib) in adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer, originally scheduled for presentation at WCLC and ESMO in 2026, were subsequently presented and posted on its website. The upcoming detailed subgroup efficacy and safety readouts for IBTROZI, building on its June 2025 US FDA approval, give investors additional...

The consensus price target hints at a 94.3% upside potential for Nuvation Bio (NUVB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss its financial results and business updates for the second quarter of 2026.

Nuvation Bio (NUVB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

According to TheFly, RBC Capital analyst Leonid Timashev said the updated long-term follow-up data reinforce safusidenib's competitive profile in IDH1-mutant glioma.

Nuvation Bio reports positive long-term Phase 2 safusidenib data for glioma patients and expands its clinical trial pipeline.

Nuvation Bio Inc. (NYSE:NUVB) is one of the best small cap stocks to buy with the highest upside potential. RBC Capital lowered the price target on Nuvation Bio Inc. (NYSE:NUVB) to $19 from $20 on July 7 and reaffirmed an Outperform rating on the shares. The rating update came as part of a broader research note […]

Nuvation Bio Inc (NYSE:NUVB) is one of billionaire David Abrams’ top stock picks with upside potential. Nuvation Bio shares gained nearly 170% over the past year, and analysts project a more than 150% upside for the stock over the next 12 months. Some 41 hedge funds are backing Nuvation Bio stock. This comes as Nuvation […]